Results 41 to 50 of about 6,032 (153)

Case report: reuse of tirofiban leads to very severe thrombocytopenia

Frontiers in Cardiovascular Medicine, 2023
BackgroundTelofiban is a class of small molecule non-peptide tyrosine derivatives containing RGD sequences. It is the only platelet surface glycoprotein (GP) IIb/IIIa receptor antagonist (GPI) currently marketed in China.
Yuqing Li, Jiuchun Qiu, Yi Gao, Guangping Li   +3 more
doaj   +1 more source

Association Discovery Approach in Healthcare Big Data to Identify Drug Safety and Drug Repurposing Signals

Clinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 228-240, January 2026.
Data science approaches have been increasingly implemented in healthcare big data to evaluate the safety and effectiveness of drugs. Association discovery is a data mining approach that finds potentially associated elements in high‐dimensional data. We present a novel implementation of the association discovery approach in longitudinal healthcare data ...
George S. Q. Tan, Lynn Miller, Sam Wade, Jenni Ilomäki, Dickson Lukose, Jia Rong, Geoffrey I. Webb   +6 more
wiley   +1 more source

Identification of Key Genes and Pathways Associated With Gender Differences in Pulmonary Arterial Hypertension Based on Bioinformatic Approaches

BioMed Research International, Volume 2026, Issue 1, 2026.
Pulmonary arterial hypertension (PAH) is a complex disease with multiple contributing factors. Epidemiological data showed that women are more susceptible to PAH, but they tend to have better right ventricular (RV) function and prognosis compared to men. The mechanisms behind these gender differences are not well understood.
Mohammad Panahi, Reyhaneh Kalhor, Mohammad-Hossein Mokhtarian, Fatemeh Javaheri Tehrani, Zinat Shams, Hourieh Kalhor, Hannah Wesley   +6 more
wiley   +1 more source

Adjunct Intraarterial or Intravenous Tirofiban Versus No Tirofiban After Successful Recanalization of Basilar Artery Occlusion Stroke: The BASILAR Registry

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Approximately half of patients who achieve successful reperfusion do not achieve functional independence. The present study sought to investigate the clinical outcomes and safety of intraarterial or intravenous tirofiban as adjunct therapy in ...
Huagang Li, Dongsheng Ju, Zhaojun Tao, Jiayin Wang, Thanh N. Nguyen, Jeffrey L. Saver, Raul G. Nogueira, Chang Liu, Qingwu Yang, Zhongming Qiu, Congguo Yin, Dong Sun, Shudong Liu   +12 more
doaj   +1 more source

Efeito protetor de antagonista das gliproteínas IIb/IIa nas alterações hepáticas e pulmonares secundárias à isquemia e reperfusão do fígado em ratos Protective effects of an inhibitor of glycoprotein IIb/IIIa in the hepatic and pulmonary disturbances secondary to ischemia and reperfusion injury of rat’s liver

Arquivos de Gastroenterologia, 2007
RACIONAL: A lesão de isquemia e reperfusão hepática é um evento comum e responsável por considerável morbidade e mortalidade. OBJETIVO: Avaliar efeitos de inibidor da glicoproteína IIb/IIIa, cloridrato de tirofiban, nas alterações hepáticas e pulmonares ...
Leonardo F. Canedo, Marcel Autran C. Machado, Ana M. M. Coelho, Sandra N. Sampietre, Telesforo Bachella, Marcel C. C. Machado   +5 more
doaj   +1 more source

Effects of Periprocedural Tirofiban vs. Oral Antiplatelet Drug Therapy on Posterior Circulation Infarction in Patients With Acute Intracranial Atherosclerosis-Related Vertebrobasilar Artery Occlusion

Frontiers in Neurology, 2020
Background and purpose: Tirofiban and oral antiplatelet drugs can be used to inhibit reocclusion and restore microvascular reperfusion during endovascular treatment (EVT).
Xuan Sun, Huijun Zhang, Xu Tong, Feng Gao, Gaoting Ma, Zhongrong Miao   +5 more
doaj   +1 more source

Efficacy and Safety of Intracoronary versus Intravenous Administration of Tirofiban during Percutaneous Coronary Intervention for Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials. [PDF]

PLoS ONE, 2015
Percutaneous coronary intervention (PCI) is known as the most effective treatment for acute coronary syndrome (ACS). However, without proper therapy and patient management, stent thrombosis after PCI may lead to another myocardial infarction. In addition
Xiuying Tang, Runjun Li, Quanmin Jing, Yingfeng Liu, Peng Liu   +4 more
doaj   +1 more source

Low-dose intravenous tirofiban infusion after endovascular recanalization for non-acute middle cerebral artery occlusion

Heliyon, 2022
Background and purpose: Endovascular recanalization for patients with symptomatic non-acute middle cerebral artery occlusion still remines challenging. Postoperative treatment is still controversial.
Zhang Xi, Chen Zhibin, Luo Yun, Duan Guangxin, Zhang He, Li Jingwei, Xu Yun   +6 more
doaj   +1 more source

Anticoagulant or Antithrombotic Therapy After Early Neurological Deterioration in Patients With Branch Atheromatous Disease Receiving Dual Antiplatelet Therapy

International Journal of Clinical Practice, Volume 2026, Issue 1, 2026.
Objective We evaluated the effectiveness and safety of adding tirofiban or argatroban after early neurological deterioration (END) in patients with branch atheromatous disease (BAD) receiving dual antiplatelet therapy and compared the outcomes with those of patients who continued dual antiplatelet therapy alone. Methods This retrospective study focused
Xuemin Zhong, Juan Yang, Ronghua Xu, Jian Wang, Nikhat Kaura   +4 more
wiley   +1 more source

There is no difference in safety and efficacy mechanical thrombectomy alone or mechanical thrombectomy with tirofiban for patients undergoing treatment of large vessel occlusion and underlying intracranial atherosclerosis

Interdisciplinary Neurosurgery, 2022
Background: Mechanical thrombectomy (MT) is a widely proven method to treat acute ischemic stroke (AIS) during mechanical thrombectomy and acute stenting and angioplasty is a topic discussed till this day regarding safety and efficacy.
Hari Movva, Rani Rabah, Wondwossen Tekle, Laurie Preston, Hari Kotta, Ameer E Hassan   +5 more
doaj   +1 more source